社论：炎症性肠病的新型治疗方法
Editorial: Novel Therapeutic Approaches in Inflammatory Bowel Diseases.
作者信息
Pallio Giovanni
机构信息
Department of Biomedical and Dental Sciences and Morphological and Functional Imaging, University of Messina, Via C. Valeria, 98125 Messina, Italy.
出版信息
Biomedicines. 2023 Sep 5;11(9):2466. doi: 10.3390/biomedicines11092466.
Abstract
Inflammatory bowel diseases (IBDs) encompass ulcerative colitis (UC) and Crohn's disease (CD), both of which are inflammatory ailments affecting the gastrointestinal tract [...].
摘要
炎症性肠病（IBDs）包括溃疡性结肠炎（UC）和克罗恩病（CD），这两种都是影响胃肠道的炎症性疾病[...]。
相似文献
1
Editorial: Novel Therapeutic Approaches in Inflammatory Bowel Diseases.社论：炎症性肠病的新型治疗方法
Biomedicines. 2023 Sep 5;11(9):2466. doi: 10.3390/biomedicines11092466.
2
Sleep disturbance and risk of active disease in patients with Crohn's disease and ulcerative colitis.睡眠障碍与克罗恩病和溃疡性结肠炎患者活动期疾病的风险。
Clin Gastroenterol Hepatol. 2013 Aug;11(8):965-71. doi: 10.1016/j.cgh.2013.01.021. Epub 2013 Feb 1.
3
Mesenchymal stem/stromal cells in the pathogenesis and regenerative therapy of inflammatory bowel diseases.间充质干/基质细胞在炎症性肠病发病机制及再生治疗中的作用
Front Immunol. 2022 Aug 4;13:952071. doi: 10.3389/fimmu.2022.952071. eCollection 2022.
4
Patients' perspectives on smoking and inflammatory bowel disease: An online survey in collaboration with European Federation of Crohn's and Ulcerative Colitis Associations.患者对吸烟与炎症性肠病的看法：与欧洲克罗恩病和溃疡性结肠炎协会合作开展的在线调查
World J Gastroenterol. 2020 Aug 7;26(29):4343-4355. doi: 10.3748/wjg.v26.i29.4343.
5
Novel Therapies and Approaches to Inflammatory Bowel Disease (IBD).炎症性肠病（IBD）的新型疗法与方法
J Clin Med. 2022 Jul 28;11(15):4374. doi: 10.3390/jcm11154374.
6
[Therapy progression in surgery of inflammatory bowel diseases].[炎症性肠病手术中的治疗进展]
Zhonghua Wei Chang Wai Ke Za Zhi. 2012 Aug;15(8):872-6.
7
Metaproteomics of fecal samples of Crohn's disease and Ulcerative Colitis.克罗恩病和溃疡性结肠炎粪便样本的代谢组学研究。
J Proteomics. 2019 Jun 15;201:93-103. doi: 10.1016/j.jprot.2019.04.009. Epub 2019 Apr 19.
8
Real-world treatment patterns and disease control over one year in patients with inflammatory bowel disease in Brazil.巴西炎症性肠病患者一年的真实世界治疗模式和疾病控制情况。
World J Gastroenterol. 2021 Jun 21;27(23):3396-3412. doi: 10.3748/wjg.v27.i23.3396.
9
Colorectal adenocarcinoma in Crohn's disease: a retrospective histologic study.克罗恩病中的结直肠癌：一项回顾性组织学研究
Dis Colon Rectum. 1997 Sep;40(9):1072-8. doi: 10.1007/BF02050932.
10
Real-World Persistence of Ustekinumab in the Treatment of Inflammatory Bowel Disease.乌司奴单抗治疗炎症性肠病的真实世界持久性。
Adv Ther. 2023 Oct;40(10):4421-4439. doi: 10.1007/s12325-023-02611-0. Epub 2023 Jul 28.
引用本文的文献
1
Pectinase responsive nanoplatform for oral targeted delivery 5-aminosalicylic acid and zinc coordination driven nanozyme in inflammatory bowel disease treatment.用于口服靶向递送5-氨基水杨酸的果胶酶响应纳米平台以及锌配位驱动的纳米酶在炎症性肠病治疗中的应用
Int J Pharm X. 2025 Jul 16;10:100362. doi: 10.1016/j.ijpx.2025.100362. eCollection 2025 Dec.
2
Therapeutic role of extracellular vesicles from human umbilical cord mesenchymal stem cells and their wide therapeutic implications in inflammatory bowel disease and other inflammatory disorder.人脐带间充质干细胞外泌体的治疗作用及其在炎症性肠病和其他炎症性疾病中的广泛治疗意义。
Front Med (Lausanne). 2024 Jul 30;11:1406547. doi: 10.3389/fmed.2024.1406547. eCollection 2024.
本文引用的文献
1
Helminth Lessons in Inflammatory Bowel Diseases (IBD).炎症性肠病（IBD）中的蠕虫学课程
Biomedicines. 2023 Apr 18;11(4):1200. doi: 10.3390/biomedicines11041200.
2
Exploring the Pipeline of Novel Therapies for Inflammatory Bowel Disease; State of the Art Review.探索炎症性肠病新型疗法的研发进程；最新技术综述
Biomedicines. 2023 Mar 1;11(3):747. doi: 10.3390/biomedicines11030747.
3
Defining the Failure of Medical Therapy for Inflammatory Bowel Disease in the Era of Advanced Therapies: A Systematic Review.定义先进疗法时代炎症性肠病的药物治疗失败：一项系统评价。
Biomedicines. 2023 Feb 13;11(2):544. doi: 10.3390/biomedicines11020544.
4
Protective Effect of Red Rice Extract Rich in Proanthocyanidins in a Murine Colitis Model.富含原花青素的红米提取物在小鼠结肠炎模型中的保护作用
Biomedicines. 2023 Jan 18;11(2):265. doi: 10.3390/biomedicines11020265.
5
Effectiveness and Safety Profiles of Biological Therapies in Inflammatory Bowel Disease: Real Life Data from an Active Pharmacovigilance Project.炎症性肠病生物疗法的有效性和安全性概况：来自一项主动药物警戒项目的真实数据
Biomedicines. 2022 Dec 18;10(12):3280. doi: 10.3390/biomedicines10123280.
6
Sirtuin 7 Inhibitor Attenuates Colonic Mucosal Immune Activation in Mice-Potential Therapeutic Target in Inflammatory Bowel Disease.沉默调节蛋白7抑制剂减轻小鼠结肠黏膜免疫激活——炎症性肠病的潜在治疗靶点
Biomedicines. 2022 Oct 25;10(11):2693. doi: 10.3390/biomedicines10112693.
7
Early Clinical Remission Is a Predictor of Long-Term Remission with the Use of Vedolizumab for Ulcerative Colitis.早期临床缓解是使用维多珠单抗治疗溃疡性结肠炎实现长期缓解的一个预测指标。
Biomedicines. 2022 Oct 9;10(10):2526. doi: 10.3390/biomedicines10102526.
8
Cannabinoid Therapeutic Effects in Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.大麻素对炎症性肠病的治疗作用：随机对照试验的系统评价和荟萃分析
Biomedicines. 2022 Sep 29;10(10):2439. doi: 10.3390/biomedicines10102439.
9
Enhanced Recovery Care versus Traditional Care after Surgery in Pediatric Patients with Inflammatory Bowel Disease: A Retrospective Case-Control Study.炎症性肠病患儿术后强化康复护理与传统护理的对比：一项回顾性病例对照研究
Biomedicines. 2022 Sep 7;10(9):2209. doi: 10.3390/biomedicines10092209.
10
Subcutaneous Infliximab [CT-P13], a True Biologic 2.0. Real Clinical Practice Multicentre Study.皮下注射英夫利昔单抗[CT-P13]，一种真正的生物制剂2.0。真实临床实践多中心研究。
Biomedicines. 2022 Aug 30;10(9):2130. doi: 10.3390/biomedicines10092130.
Zotero 插件